EA036671B1 - Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a - Google Patents

Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a Download PDF

Info

Publication number
EA036671B1
EA036671B1 EA201790549A EA201790549A EA036671B1 EA 036671 B1 EA036671 B1 EA 036671B1 EA 201790549 A EA201790549 A EA 201790549A EA 201790549 A EA201790549 A EA 201790549A EA 036671 B1 EA036671 B1 EA 036671B1
Authority
EA
Eurasian Patent Office
Prior art keywords
vegf
level
patient
patients
aflibercept
Prior art date
Application number
EA201790549A
Other languages
English (en)
Russian (ru)
Other versions
EA201790549A1 (ru
Inventor
Таша Николль Симс
Бо Гао
Израэль Лови
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201790549A1 publication Critical patent/EA201790549A1/ru
Publication of EA036671B1 publication Critical patent/EA036671B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201790549A 2014-09-16 2015-09-10 Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a EA036671B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US201562099630P 2015-01-05 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
EA201790549A1 EA201790549A1 (ru) 2017-07-31
EA036671B1 true EA036671B1 (ru) 2020-12-07

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790549A EA036671B1 (ru) 2014-09-16 2015-09-10 Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a

Country Status (12)

Country Link
US (2) US10525104B2 (enExample)
EP (1) EP3194974B1 (enExample)
JP (1) JP6692358B2 (enExample)
KR (1) KR102471057B1 (enExample)
CN (1) CN107076749B (enExample)
AU (1) AU2015318207B2 (enExample)
CA (1) CA2960890A1 (enExample)
EA (1) EA036671B1 (enExample)
IL (1) IL250905B (enExample)
MX (1) MX382673B (enExample)
WO (1) WO2016044041A1 (enExample)
ZA (1) ZA201701664B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11699527B2 (en) 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
CA3058129C (en) * 2017-03-31 2023-04-18 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
JP2022541689A (ja) * 2019-07-13 2022-09-26 オートレイシーズ，インク． 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
IN2012DN02046A (enExample) * 2009-08-14 2015-08-21 Allergan Inc
CN102711830A (zh) 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HIDETOSHI HAYASHI, TOKUZO ARAO, KAZUKO MATSUMOTO, HIDEHARU KIMURA, YOSUKE TOGASHI, YOSHINORI HIRASHIMA, YOSUKE HORITA, SATORU IWAS: "Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma", ONCOTARGET, UNITED STATES, 15 May 2014 (2014-05-15), United States, pages 2588, XP055163018, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/24809949> DOI: 10.18632/oncotarget.1811 *
J M J�RGENSMEIER, H-J SCHMOLL, J D ROBERTSON, L BROOKS, M TABOADA, S R MORGAN, D WILSON, P M HOFF: "Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 108, no. 6, 2 April 2013 (2013-04-02), GB, pages 1316 - 1323, XP055230575, ISSN: 0007-0920, DOI: 10.1038/bjc.2013.79 *
J. L. SPRATLIN, COHEN R. B., EADENS M., GORE L., CAMIDGE D. R., DIAB S., LEONG S., O'BRYANT C., CHOW L. Q.M., SERKOVA N. J., MEROP: "Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 28, no. 5, 10 February 2010 (2010-02-10), US, pages 780 - 787, XP055230184, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.23.7537 *
P. S. HEGDE, A. M. JUBB, D. CHEN, N. F. LI, Y. G. MENG, C. BERNAARDS, R. ELLIOTT, S. J. SCHERER: "Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 4, 15 February 2013 (2013-02-15), US, pages 929 - 937, XP055230578, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2535 *
WEIJING SUN, ANUJ PATEL: "Ziv-aflibercept in metastatic colorectal cancer", BIOLOGICS: TARGETS AND THERAPY, pages 13, XP055230180, DOI: 10.2147/BTT.S39360 *

Also Published As

Publication number Publication date
WO2016044041A1 (en) 2016-03-24
AU2015318207A1 (en) 2017-04-06
EA201790549A1 (ru) 2017-07-31
US10525104B2 (en) 2020-01-07
CN107076749B (zh) 2020-12-29
EP3194974B1 (en) 2019-10-23
MX382673B (es) 2025-03-13
ZA201701664B (en) 2018-05-30
MX2017003387A (es) 2018-01-30
JP2017530372A (ja) 2017-10-12
JP6692358B2 (ja) 2020-05-13
IL250905B (en) 2019-12-31
AU2015318207B2 (en) 2021-11-04
KR102471057B1 (ko) 2022-11-28
IL250905A0 (en) 2017-04-30
CA2960890A1 (en) 2016-03-24
KR20170055972A (ko) 2017-05-22
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
US20200129589A1 (en) 2020-04-30
US20170281725A1 (en) 2017-10-05
US11439683B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
US11439683B2 (en) Anti-angiogenic therapy of metastatic colorectal cancer
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
DK2743697T3 (en) METHODS OF IN VITRO DIAGNOSTICS OF INVASIVE CARCINOMS
KR20140094594A (ko) 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커
JP2017524127A (ja) 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
KR20120123248A (ko) 악성 종양의 진단 방법
HK1202334A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2023190820A1 (ja) 抗ＣＫ２α抗体又はその断片
KR20250136412A (ko) Pro-c5 분석법
HK1198063A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
HK1181459B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
HK1184854B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer